跳转至内容
Merck
CN

SML3051

Sigma-Aldrich

Emtricitabine

≥98% (HPLC), nucleoside reverse transcriptase inhibitor, powder

别名:

(-)-FTC; (-)-2′,3′-Dideoxy-5-fluoro-3′-thiacytidine, (2R-cis)-4-Amino-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone, 4-Amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone, 5-Fluoro-1-(2R,5S)-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine, 524W91, BW 1592, BW 524W91, BW-1592, BW-524W91, BW1592, BW524W91, (−)-2′3′-Dideoxy-5-fluoro-3′-thiacytidine, (2R,5S)-4-Amino-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one, FTC

登录查看公司和协议定价

选择尺寸

关于此项目

经验公式（希尔记法）:
C8H10FN3O3S
化学文摘社编号:
143491-57-0
分子量:
247.25
UNSPSC代码:
12352200
NACRES:
NA.77

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

Emtricitabine, ≥98% (HPLC)

质量水平

100

方案

≥98% (HPLC)

表单

powder

旋光性

[α]/D -150 to -125°, c = 0.25 in methanol

颜色

white to beige

溶解性

DMSO: 2 mg/mL, clear

储存温度

2-8°C

SMILES字符串

FC1=CN(C(=O)N=C1N)[C@H]2O[C@H](SC2)CO

InChI

1S/C8H10FN3O3S/c9-4-1-12(8(14)11-7(4)10)5-3-16-6(2-13)15-5/h1,5-6,13H,2-3H2,(H2,10,11,14)/t5-,6+/m0/s1

InChI key

XQSPYNMVSIKCOC-NTSWFWBYSA-N

正在寻找类似产品? 访问 产品对比指南

相关类别

生化/生理作用

Emtricitabine ((-)-FTC) is an orally active, non-cytotoxic (>100 μM/PBM, CEM, Vero, MT-4), potent nucleoside reverse transcriptase inhibitor (NRTI) against HIV type 1/2 (HIV-1 IC50/culture = 8 nM/PBM (LAV-1), 9 nM/CEM (LAV-1); HIV-2 IC50/culture = 0.7 nM/PBM (ROD2), 100 nM/CEM (Zy)), hepatitis B, as well as simian and feline immunodeficiency viruses. Emtricitabine is activated via 2′-deoxycytidine kinase-mediated phosphorylation to (-)-FTC-5′-triphosphate that inhibits viral reverse transcriptase in a dCTP-competitive manner (HIV-1 Ki = 2.9 μM).

储存分类代码

11 - Combustible Solids

WGK

WGK 1

闪点(°F)

Not applicable

闪点(°C)

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000446005
0000446005
0000402761
0000402760
0000328198

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

R F Schinazi et al.
Antimicrobial agents and chemotherapy, 36(11), 2423-2431 (1992-11-01)
2',3'-Dideoxy-5-fluoro-3'-thiacytidine (FTC) has been shown to be a potent and selective compound against human immunodeficiency virus type 1 in acutely infected primary human lymphocytes. FTC is also active against human immunodeficiency virus type 2, simian immunodeficiency virus, and feline immunodeficiency
Koen K A Van Rompay et al.
Journal of virology, 76(12), 6083-6092 (2002-05-22)
Drug-resistant mutants with a methionine-to-valine substitution at position 184 of reverse transcriptase (M184V) emerged within 5 weeks of initiation of therapy in four newborn macaques infected with simian immunodeficiency virus (SIVmac251) and treated with lamivudine (3TC) or emtricitabine [(-)-FTC] (two
Michele B Daly et al.
PloS one, 14(11), e0225146-e0225146 (2019-11-16)
Macaque models of simian or simian/human immunodeficiency virus (SIV or SHIV) infection are critical for the evaluation of antiretroviral (ARV)-based HIV treatment and prevention strategies. However, modelling human oral ARV administration is logistically challenging and fraught by limited adherence. Here
Richard Hazen et al.
Journal of acquired immune deficiency syndromes (1999), 32(3), 255-258 (2003-03-11)
To assess the relative in vitro potency of the antiviral agents emtricitabine (FTC), lamivudine (3TC), and zidovudine (ZDV) in peripheral blood mononuclear cells (PBMCs), monocyte-derived macrophages, and MT-4 cells infected with HIV-1. DESIGN In vitro evaluation of the test compounds
S K Ono et al.
The Journal of clinical investigation, 107(4), 449-455 (2001-02-22)
After receiving lamivudine for 3 years to treat chronic hepatitis B, 67-75% of patients develop B-domain L528M, C-domain M552I, or M552V mutations in the HBV polymerase that render hepatitis B virus (HBV) drug-resistant. The aim of this study was to
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持